Delayed Hematological Remission Predicts Poor Renal Outcome in Children with Atypical Hemolytic Uremic Syndrome

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is hemolytic uremic syndrome (HUS) without a coexisting disease or specific infection. Eculizumab is the standard of care for children with aHUS. However, since it is not yet available in India, plasma therapy remains the treatment of choice in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Singhal, Jyoti, Gupta, Rashi A., Sharma, Jyoti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208542/
https://www.ncbi.nlm.nih.gov/pubmed/37234434
http://dx.doi.org/10.4103/ijn.ijn_484_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208542/
https://www.ncbi.nlm.nih.gov/pubmed/37234434
http://dx.doi.org/10.4103/ijn.ijn_484_21

Ejemplares similares